Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
02:01pm, Tuesday, 01'st Apr 2025
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
01:39pm, Tuesday, 01'st Apr 2025
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Tuesday, 01'st Apr 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
08:38am, Tuesday, 01'st Apr 2025
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, the active ingredient in Lilly's obesity drug Zepbound and diabetes drug Moun
Where Will Eli Lilly Be in 1 Year?
05:37am, Tuesday, 01'st Apr 2025
Pharmaceutical powerhouse Eli Lilly (LLY 0.37%) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for treating t
Lilly sues two compounders over copies of weight-loss drugs
05:09am, Tuesday, 01'st Apr 2025
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
06:51pm, Monday, 31'st Mar 2025
In the most recent trading session, Eli Lilly (LLY) closed at $825.91, indicating a +0.41% shift from the previous trading day.
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
02:34pm, Monday, 31'st Mar 2025
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 30
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
02:31pm, Sunday, 30'th Mar 2025
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk factor for heart disease in a midstage trial, according to data presented a
In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data were p
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
05:00am, Sunday, 30'th Mar 2025
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of drugs a
1 Growth Stock With Major Catalysts on the Way to Buy and Hold
03:13am, Sunday, 30'th Mar 2025
After starting 2024 strong, Eli Lilly (LLY -0.16%) did not perform well in the second half of last year. Its financial results, though solid compared to similarly sized peers, were not always up to in
2 healthcare safe bets to buy ahead of Trump's pharmaceutical tariffs
05:29pm, Saturday, 29'th Mar 2025
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates inv
2 healthcare stocks to buy ahead of Trump's pharmaceutical tariffs
05:29pm, Saturday, 29'th Mar 2025
United States President Donald Trump has hinted that the pharmaceutical sector will likely be the next to be hit with tariffs. While announcing on March 28, Trump did not specify the date or rates inv
Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop
06:37pm, Friday, 28'th Mar 2025
LLY RISES 8 POINTS AFTER ALERT
